Abstract
Heterogeneity and high versatility are the characteristic features of the cells of monocyte-macrophage lineage. The mononuclear phagocyte system, derived from the bone marrow progenitor cells, is primarily composed of monocytes, macrophages, and dendritic cells. In regenerative tissues, a central role of monocyte-derived macrophages and paracrine factors secreted by these cells is indisputable. Macrophages are highly plastic cells. On the basis of environmental cues and molecular mediators, these cells differentiate to proinflammatory type I macrophage (M1) or anti-inflammatory or proreparative type II macrophage (M2) phenotypes and transdifferentiate into other cell types. Given a central role in tissue repair and regeneration, the review focuses on the heterogeneity of monocytes and macrophages with current known mechanisms of differentiation and plasticity, including microenvironmental cues and molecular mediators, such as noncoding RNAs.
The concept of cell plasticity originated from the ability of adult stem cells to differentiate into multiple cell types. Heterogeneity and plasticity are the characteristic features of the cells of the monocyte-macrophage lineage.1 In response to the cues from local milieu, these cells have the ability to undergo phenotypic/functional switch. In addition to switching between polarization states, these cells may transdifferentiate into endothelial or other cells in vitro and in vivo. In the current review, we focus on the heterogeneity and plasticity of monocytes and macrophages. The plasticity of macrophages plays a decisive role in tissue repair and regeneration. Herein, we discuss the current known mechanisms, including the roles of microenvironmental cues and molecular mediators, such as noncoding RNAs, underlying the plasticity and differentiation of macrophages in tissue repair and regeneration.
Mononuclear Phagocyte System
The mononuclear phagocyte system (MPS), originating from bone marrow progenitor cells, is composed of monocytes, macrophages, and dendritic cells (DCs), with phenotypic and functional overlaps between these cells.2 These cells differentiate and enter the systemic circulation to form monocytes, and then infiltrate into tissues to become macrophages.3 The other cells of the MPS (ie, DCs and macrophages) also have a remarkable heterogeneity related to their origin, phenotype, tissue localization, proliferative potential, and functions.1,4 Cells of MPS display plasticity in their gene expression patterns, thus identification based upon surface markers is often challenging.5 Activating the cells of the MPS by macrophage colony stimulating factor (MCSF)-1 and IL-34 results in proliferation as well as differentiation of these cells.6 The differentiation of DCs from hematopoietic stem and progenitor cells may occur inside extramedullary tissues.7
Monocyte Origin, Function, and Heterogeneity
Monocytes correspond to 10% or 4% of leukocytes in human or murine blood, respectively. In addition to playing a critical role in development, homeostasis, and inflammation, they are also responsible for the removal of apoptotic and necrotic cells.8 The monocytes originate from hematopoietic stem cell (HSC) monoblasts that differentiate to promonocytes and then to mature monocytes. (Figure 1).9 A clear understanding of monocyte heterogeneity is lacking, but it is suggested that monocytes mature in the blood and then get recruited to injury sites. The point at which these cells start their journey from blood may define their functions.10
In mice, two populations of monocytes have been identified and named as inflammatory and patrolling monocytes, depending on the time they spend in the blood before migrating to tissues.11 The Nomeclature Committee of the International Union of Immunologic Societies (Berlin, Germany) has recently approved a new nomenclature of monocytes in humans. According to this new system, the monocyte population has been divided into three subsets: i) the major, or classical, population of human monocytes (90%) with high CD14 but no CD16 expression (CD14+CD16−); ii) the intermediate subset (CD14+CD16+), and iii) the low CD14- but high CD16-expressing or nonclassical subset (CD14dimCD16+).12 Human classical and intermediate monocyte subsets that display inflammatory properties are referred to as inflammatory monocytes whereas the nonclassical monocyte subset demonstrates crawling or patrolling behavior along blood vessel walls. These cells are known to respond to viral infection. The plasticity of the inflammatory monocytes enables them to alter their phenotype based on the environment and/or the immune responses elicited after exposure to a particular pathogen.13
Although contentious, inflammatory monocytes have been reported to produce patrolling monocytes in the blood or bone marrow.13 A rare subset of monocytes is known to express TIE2, the receptor for angiopoietins, and is therefore termed TIE2-expressing monocytes.14 The TIE2-expressing monocytes and intermediate (CD14+CD16+) subsets of monocytes with high angiogenic potential have been associated with liver regeneration.14 Another example of involvement of monocytes in tissue regeneration is based on the observation that the osteoclasts of the regenerating salamander limb form by fusion of monocytes.15 These studies suggest involvement of specific subsets of monocytes in the tissue regeneration process.
DC Origin, Function, and Heterogeneity
DCs are essential mediators of innate and adaptive immune responses.16 The function and phenotypes of dendritic cells subsets remains to be elucidated.16 Relative to other cells of the MPS, our understanding of the molecular mechanisms that regulate the development of DCs is limited. DCs are composed of distinct subsets for which precise functions and interrelationships remain to be elucidated. The advances in establishing classic DCs as a distinct lineage among myeloid cells and their function in vivo have been recently reviewed.16 Because of relative rarity and phenotypic similarity to other cells of the MPS, their role in wound healing is not well described. Among DCs, the plasmacytoid DCs, which are normally not found in healthy skin, have been shown to rapidly infiltrate skin wounds with quick kinetics, similar to that of neutrophils.17 Whether such infiltration of plasmacytoid DCs into wounds is a general occurrence or is associated with conditions such as infection, remains to be tested. Plasmacytoid DCs, a rare population of circulating cells, produce high quantities of type I interferons (IFN) when exposed to viral infections.18
Macrophages
Origin, Functions, and Steady-State Tissue Distribution
Considered to be important immune effector cells of the innate immune system, macrophages not only provide the initial defense against microorganisms but also initiate and control the adaptive immune responses.19 Ilya Mechnikov, a Russian-French biologist, discovered in 1884 that certain white blood cells engulf and digest bacteria by a process that he referred to as phagocytosis, and the cells were named macrophages (derived from the Greek words makros, big, and phagein, to eat).20 Apart from being involved in producing required growth factors, macrophages are pivotal in tissue repair, remodeling, and synchronizing metabolic functions.21,22 Macrophages efficiently clear apoptotic polymorphonuclear leukocytes, a prerequisite for a favorable resolution of inflammation,23 by efferocytosis (phagocytosis of apoptotic cells).24 A dysregulation in macrophage efferocytosis may lead to autoimmunity and persistent inflammatory diseases.25
Circulating blood monocytes were believed to be the exclusive precursors of tissue macrophages.26 Monocytes derived from the bone marrow differentiate to macrophages in the intestine and the dermis during acute infection and inflammation.27 However, reports indicate that macrophages in tissues like the liver and spleen originate from embryonic precursors derived from the yolk sac and self-replenish themselves.28
Although macrophages in tissues have many features in common, they are nevertheless extremely heterogeneous in terms of function and surface marker expression29 (Table 1).30–50 The anatomical location of the macrophages dictates their heterogeneity in terms of their function.9 In the white adipose tissue, the number and the activation state of the macrophages determine the metabolic health of adipocytes, which, in turn, regulate the metabolism in the white adipose tissue through the release of hormones called adipokines.51,52 Macrophages present in the brown adipose tissue are required to enable the metabolic acclimatization to cold.53 The resident macrophages of the liver (alias Kupffer cells) comprise the largest section of tissue macrophages in the body54 that expedite the metabolic adaptations of hepatocytes during high caloric intake.53 Alveolar macrophages in the lungs phagocytose any potentially harmful pathogen that is taken in from the air during respiration.55 Interestingly, the cervical region consists of both proinflammatory type I macrophage (M1) and anti-inflammatory or propreparative type II macrophage (M2) phenotypes (discussed later), which are possibly responsible for the maternal tissue repair after birth. Increased presence of M2 macrophages during labor and immediately after birth suggests a key role of M2 macrophages in maternal tissue repair after birth.56 Macrophages abundantly present in tumors are called tumor-associated macrophages (TAMs).57 Unlike the other tissue-resident macrophages, TAMs represent more of an M2 phenotype.57 M2-like TAMs in established tumors endorse tumor-induced immunosuppression, suggesting a switch of macrophage phenotype from M1 during tumor onset to M2 in established tumors.58–60
Table 1.
Tissues/organs | Name of cells | Major functions |
---|---|---|
Wound | Wound macrophages | Scavenging,30 phagocytosis,31 efferocytosis,32 antigen presentation,33 promotion of repair,30,34 extracellular signaling,35 and angiogenesis34,36 |
Central nervous system | Microglial cells | Scavenging,37 phagocytosis,38 cytotoxicity,39 antigen presentation,40 synaptic stripping,41 promotion of repair,42 and extracellular signaling43 |
Lungs | Alveolar macrophages | Efferocytosis,44 phagocytosis,45 and surfactant homeostasis46 |
Connective tissue | Histiocytes | Phagocytosis47 and antigen presentation47 |
Liver | Kupffer cells | Endocytic activity against blood-borne materials entering the liver48 and host defense49 |
Bone | Osteoclasts | Bone resorption50 |
Plasticity and Polarization
Macrophages and their activation states are characterized by plasticity and flexibility.19,57,61 Depending on the environmental stimuli, macrophages have a wide array of functions, especially in the modulation of innate immune response through the release of several factors.62 In fact, some of these activities of macrophages are opposing. The diverse roles (ie, proinflammatory or anti-inflammatory nature of macrophages in immune responses) depend on the environmental stimuli that induce the macrophages to acquire a distinct functional phenotype.62 Although the microenvironmental stimuli and the phenotypes are diverse, macrophages have been primarily classified into two major phenotypes on the basis of the type 1 helper T-cell (Th1)/type 2 helper T-cell (Th2) polarization, according to the T-cell literature.9,30,57,63 As per the Th1/Th2 concept, cytokines such as IFN-γ and tumor necrosis factor-α (TNF-α), which are predominantly secreted by Th1 cells, activate macrophages to classically activated M1 macrophages. However, Th2 cytokines such as IL-4 and IL-10 have been found to inhibit macrophage activation, and these macrophages are referred to as anti-inflammatory M2 macrophages (Figure 2).64,65 Essential for early stages of tissue repair, M1 macrophages support pathogen killing and IL-12–mediated Th1 responses whereas reparative M2 macrophages support the effector functions of Th2 thymocytes and aid in the later stages of the repair process (Figure 3).
On the basis of the stimulus from the microenvironment, M2 macrophages are further subdivided into three subtypes: i) M2a is a profibrotic phenotype and is stimulated by IL-4 or IL-13,66 ii) M2b is induced by combined exposure to immune complexes and Toll-like receptor or IL-1 receptor agonists,67 and iii) M2c is stimulated by IL-10, transforming growth factor (TGF)-β, or glucocorticoids and not only causes suppression of inflammation but also promotes neovascularization.66 Microbicidal M1 macrophages utilize nitric oxide released by the increased levels of inducible nitric oxide synthase.68 Metabolism of arginine is rerouted by M2 macrophages to produce ornithine and polyamine, thereby fostering cell growth and leading to tissue repair.69 Macrophages are key players involved in the shift from the inflammatory to the proliferative phase, which decides the fate of the injury site. By releasing a wide array of growth factors and cytokines, macrophages recruit other cell types, such as fibroblasts, which, once activated, organize the new tissue matrix and promote angiogenesis. Macrophages are also known to modulate fibrosis and scarring during the reparative process of wound healing (Figure 3).70
Wound Macrophages
The macrophages that infiltrate the wounds are often referred to as wound macrophages. Studies performed to characterize wound macrophage phenotypes in our and other laboratories suggest that macrophage polarization state at the repair site is highly dynamic and is dependent on the wound environment. Therefore, at a given time, a continuum of macrophage polarization states is expected at the wound site. Mouse wound inflammation studies have suggested that, in early phase, the phenotype of wound macrophages partly displays features of the originator monocytes. These features changed with time to present a phenotype that did not correspond to the established classification system (ie, M1 or M2).71 Daley et al72 reported that wound macrophages share the characteristics of both classically and alternatively activated macrophages. The production of proinflammatory cytokines, such as TNF-α and IL-6, was more in day 1 wound macrophages, whereas day 7 wound macrophages produced more TGF-β.72 The study also reported that, unlike the regulatory macrophages, wound macrophages did not release IL-10.72 This observation of IL-10 is contentious because studies from our laboratory clearly demonstrated production of IL-10 by wound macrophages, with a significant increase in the levels at a late phase of healing versus an early phase of wound healing.73 Our laboratory provided first evidence on the gene expression profile of wound macrophages extracted from chronic human wounds.74 Genome-wide screening for transcripts that were differentially expressed in chronic wound macrophages compared with blood monocyte–derived macrophages resulted in the identification of a focused set of 202 up-regulated and 49 down-regulated probe sets. These data suggest that wound macrophages have unique characteristics compared with cultured blood monocyte–derived macrophages.74
The paradigm of wound macrophages is unique and led to an interesting model of in vivo macrophage classification, which was proposed by Mosser and Edwards.19 According to this classification, instead of phenotypic markers, macrophages are classified on the basis of functions—host defense, wound healing, and immune regulation.19 This method is helpful because instead of two groups of macrophages, this concept provides a continuum of macrophage population on the basis of their function. The approach of classification of Mosser and Edwards19 is helpful in accommodating the macrophages that share the phenotypes of both populations, such as in wound healing. As per current literature, the macrophage polarization states have been defined using multiple terminologies such as M1 or classical and M2 or alternative. These terminologies are often contentious and confusing.75 To establish a uniform nomenclature system for macrophage activation states, a novel system based on source, activators, and markers associated with macrophage activation has been proposed.75
Can Macrophages Switch Polarization State?
It is contentious whether the alternatively activated reparative macrophages that are predominant at an injury site during the repair phase are derived from a subset of entirely newly recruited monocytes or result from M1 macrophages switching their phenotype.73 There are three major hypotheses attempting to explain the phenomenon.12 Specific subsets of monocytes can assume a specific phenotype. For example, Ly6C+ monocytes become M1 macrophages, and Ly6C− monocytes become M2 macrophages. However, the observations that Ly6C− cells differentiate to M1 and Ly6C+ cells to M212 as well as differentiation of M1 to M223,76 weaken this argument. The second view proposes that monocytes are recruited as waves into a tissue during inflammatory response. Monocytes recruited into the tissue at different times come across different microenvironmental signals that can polarize them into specific phenotypes, depending on early versus late inflammatory phase. The observation that M2 macrophages derive largely from M1 macrophages23,76 does not support the second view as well. The third view suggests that, depending on environmental cues, macrophages can differentiate from an M1 to an M2 phenotype. Porcheray et al76 investigated whether the same macrophage population involved in inflammatory response switches to a more reparative phenotype in the later phase of healing. It was clearly demonstrated that the activation state of the macrophages was rapidly and fully reversible, suggesting that a given cell may participate sequentially in both the induction and the resolution of inflammation.76 Studies from our laboratory also support the third view. We have demonstrated that successful efferocytosis and molecular mediators, such as miR-21, switch macrophages to an anti-inflammatory phenotype that helps in the resolution of inflammation.23,73 Such switching from a proinflammatory to an anti-inflammatory phenotype was facilitated by modifying intracellular noncoding miRNA, miR-21 or miR-21 target proteins phosphatase and tensin homolog (PTEN) and programmed cell death 4 (PDCD4) levels.23 Earlier, we had demonstrated that under conditions of diabetes, a dysfunction in efferocytosis, forces wound macrophages to remain in a proinflammatory (M1) phase.73
The conversion of proinflammatory M1 macrophages to anti-inflammatory M2 macrophages is beneficial in circumstances where resolution of inflammation is required, as in wound healing. However, in cancer, macrophages tend to harbor more of an anti-inflammatory M2 phenotype, where conversion to an M1 phenotype might aid in removal of cancer cells. Lipopolysaccharide (LPS) has been reported to induce an M1 phenotype from an M2 phenotype.77 Furthermore, tumor-mediated M2-like macrophages can be reprogrammed to M1-like cells by activation of CD40 using IFN-γ.78 Furthermore, reports have indicated that when fully polarized M2 macrophages present antigen to Th1 cells in a tumor milieu, this interaction results in repolarization of M2 to M1 macrophages.79
Metabolic Reprogramming in Macrophage Plasticity
An excellent review recently highlighted the significance of metabolic state in macrophage plasticity.69 Tracer-based studies using [1,2-13C2] glucose suggest that activated macrophages are glycolytic cells and that the metabolic pathway clearly differs in M1 and M2 subsets.80 In M1 macrophages, upon activation, aerobic glycolysis is induced, resulting in increased glucose uptake. Concomitantly, the induction of a pentose phosphate pathway occurs. The pentose phosphate pathway provides NADPH for the production of reactive oxygen species (ROS) and attenuation in mitochondrial respiratory change, resulting in augmented ROS production. M2 macrophages, on the other hand, use fatty acid oxidation. Inducing oxidative metabolism can switch M1 macrophages to an M2 phenotype.69 Activation of phosphofructokinase 2 isoenzymes acts as a switch between differential metabolic states of M1 and M2 macrophages.80 The dissimilarities in the metabolic states of M1 and M2 are well accepted. However, the underlying mechanisms involved in switching between metabolic states are not well understood.69
Mechanisms of Macrophage Polarization and Plasticity
Macrophages respond to environmental cues (eg, microbial products, damaged cells, and activated lymphocytes) with the acquisition of distinct functional phenotypes. Macrophage plasticity is extended to other cell types too, because they have been shown to transdifferentiate to endothelial cells.81,82 Transcriptional regulation of macrophage polarization (signal transducer and activator of transcription, interferon regulatory factor, and peroxisome proliferator-activated receptor γ) in activation of M1 or M2 polarization has been comprehensively reviewed.83 This review, therefore, has been limited to discussion on novel mechanistic underpinning of polarization. Among other regulators, phospholipase C β2, responsible for catalyzing the formation of inositol 1,4,5-trisphosphate and diacylglycerol from phosphatidylinositol 4,5-bisphosphate, has been implicated in switching of macrophages from M1 to M2 phenotype.84 Macrophages lacking src homology 2–containing inositol phosphatase exhibit elevated phosphatidylinositol (3,4,5)-trisphosphate levels, which switch nitric oxide–producing M1 macrophages to reparative M2 macrophages, suggesting that src homology 2–containing inositol phosphatase suppresses the production of M2 macrophages.85
Cell Signaling Mediators
The cAMP response element-binding protein is a crucial transcription factor for up-regulating IL-10 and arginine-1, which are associated with the M2 phenotype, and repressing M1 activation. Deletion of two cAMP response element-binding protein binding sites from the CCAAT/enhancer-binding protein β (C/EBPβ) gene promoter blocks the downstream induction of anti-inflammatory genes associated with M2-like macrophage activation. Mice carrying the mutated C/EBPβ promoter, upon muscular injury, efficiently clear injured muscle from necrotic debris, but display severe defects in muscle fiber regeneration. This confirms the persistence of inflammatory macrophages in damaged muscles of these mice.86 Interestingly, increased AMP protein kinase activity has been associated with a decreased proinflammatory status of macrophages.87 Indeed, AMP protein kinase α1 knockout macrophages fail to adopt an anti-inflammatory (M2) phenotype and display a defect in the phagocytic activity.88
In skeletal muscle wounds, mitogen-activated protein kinase phosphatase (MKP)-1 facilitates transition from M1 to M2 phenotype.89 Gene-expression analyses on MKP-1−/− muscle macrophages indicate that MKP-1 controls the inflammatory response and the switch from early proinflammatory to late anti-inflammatory macrophage phenotype via p38 mitogen-activated protein kinase down-regulation. Mice deficient in MKP-1 display defective muscle regeneration with persistence of damage and impaired growth of regenerating myofibers. The wild-type phenotype is restored by MKP-1+/+ bone-marrow transplantation.89
A key molecule of signal transduction pathway Akt also contributes to macrophage polarization, depending on its isoform. Akt1 ablation in macrophages produces an M1 macrophage phenotype, and Akt2 ablation results in an M2 phenotype.90 Akt2−/− mice are more resistant to LPS-induced endotoxin shock and to dextran sulfate sodium–induced colitis than wild-type mice, whereas Akt1 ablation renders the mice more sensitive to LPS-induced endotoxin shock.90
Furthermore, it has been shown that recepteur d'origine nantais (RON) receptor tyrosine kinase drives macrophage polarization to M2. RON knockout mice are sensitive to LPS challenge.91 RON signaling decreases proinflammatory cytokine production, suppresses nitric oxide synthase, and, at the same time, up-regulates arginase.92
The presence of macrophages at a wound site in the early phase of healing, characterized by low oxygen levels,93 suggests a role of hypoxia in macrophage phenotype and function. Indeed, the transcription factor hypoxia-inducible factor (HIF) plays a critical role in the adaptation of macrophages at the injury site.69 HIF1α and HIF2α have been implicated in M1 and M2 phenotypes, respectively. Such differential roles of HIF isoforms in macrophage polarization at the wound site are not clearly understood yet.69
miRNA and Long Noncoding RNAs
miRNAs are short noncoding RNAs of approximately 21 to 23 nucleotides in length. The database of miRNAs, miRBase, enlists 30,424 mature miRNA sequences across different species (miRBase; University of Manchester, Manchester, UK; http://www.mirbase.org, database version 20). miRNAs are primarily involved in post-transcriptional silencing of genes. They bind to the target mRNA transcripts leading to translational repression or degradation of mRNA transcripts. This pairing between miRNA and mRNA is usually of partial complementarity, resulting in a single miRNA targeting numerous mRNA transcripts. A single miRNA, on average, is predicted to target approximately 200 mRNA transcripts.94 What makes this regulatory network even more interesting is the observation that a single mRNA is targeted by more than one miRNA, depending on the length of the 3′-untranslated region of the mRNA. Recent studies, including those in our laboratory, emphasize the role played by miRNAs in regulating macrophage plasticity.
The miRNA let-7c promotes M2 macrophage polarization and suppresses M1 polarization.95 The let-7c down-regulates C/EBP-δ, an important transcriptional factor that is required for a sustained Toll-like receptor 4–induced inflammatory response, which promotes the M1 phenotype.95,96 Similar to the role of let-7c, miR-124 diminishes M1 polarization and enhances M2 polarization in bone marrow–derived macrophages from mice. Overexpression of miR-124 reduces expression of the surface markers CD45, CD11b, F4/80, major histocompatibility complex class II, and CD86, but increases the expression of the M2 phenotypic markers found in inflammatory zone 1 (FIZZ1) and arginine-1. In contrast, knockdown of miR-124 enhances the expression of the surface markers CD45 and major histocompatibility complex class II in bone marrow–derived macrophages.97
C/EBP-α was identified as the mediator of the effect of miR-124 on macrophage polarization. Such as let-7c and miR-124, miR-223 promotes the M2 fate. miR-223 is induced upon LPS treatment but is down-regulated when treated with IL-4.98 miR-223–deficient macrophages were hypersensitive to LPS stimulation, whereas such macrophages exhibited delayed responses to IL-4 compared with controls.98 The polarization was mediated via Pknox1, a proinflammatory gene that was identified in these studies as a target of miR-223. Our group has reported that miR-21 enables efficient resolution of inflammation in postefferocytosis macrophages. We speculate that such resolution of inflammation will drive macrophages toward the M2 phenotype via PTEN–NF-κB and PDCD4–activator protein 1 pathways.23
Apart from small noncoding RNAs, long noncoding RNAs (lncRNAs) are also emerging as factors that might influence macrophage plasticity. Although direct evidence of lncRNAs in determining macrophage fate is lacking, their influence on the process cannot be ruled out on the basis of upcoming reports. lncRNA E330013P06 overexpression in macrophages induced proinflammatory genes and enhanced responses to inflammatory signals.99 Similarly, studies with linc1992 demonstrated that this lncRNA forms a heterogeneous nuclear ribonucleoprotein L that may regulate transcription of the TNF-α gene by binding to its promoter. Knockdown of linc1992 caused dysregulation of TNF-α during innate activation of human leukemic cell line macrophages.100
Lipid Mediators
The role of lipid and lipoprotein molecules adds a novel element to the regulation of macrophage polarization. Oxidized low-density lipoprotein regulates the gene expression profile of M1 and M2 macrophages derived from cultured human monocytes.101 Molecular network analysis showed that most of the molecules in the oxidized low-density lipoprotein–induced M1 macrophages are directly or indirectly related to TGF-β1.101 Furthermore, it has been well documented that chemical mediators biosynthesized from arachidonic acid, which include prostaglandins and leukotriene B4, are involved in the activation of the initial phase of diapedesis.102,103 Lipid molecules derived from ω-3 polyunsaturated fatty acid substrates play multiple roles, including stimulation of macrophage efferocytosis, IL-10 production, and resolution of inflammation. Resolvin E1, an eicosapentaenoic acid family member, promotes phagocytosis at concentrations as low as 1 nmol/L. In addition, the NADPH oxidase mediated ROS generation and IL-10 production was induced.104 Maresin derived from docosahexaenoic acid acts as a switch from M1 to M2 transition.105
Macrophage Plasticity
Transdifferentiation
The major goal of tissue regeneration is to replace the injured tissue to near original. Transdifferentiation (ie, switch to another cell type) and reprogramming (ie, induction to become pluripotent cells) are critical processes of the regenerative process. Herein, we describe the significance of these processes in the context of macrophage plasticity. The ability of macrophages to transdifferentiate into endothelial cells, endothelial progenitor cells, or endothelial-like cells both in vitro and in vivo has been documented.106,107 The generation of endothelial progenitor cells from macrophages is crucial given the fact that this aspect of macrophage plasticity could be used to stimulate the revascularization of injured blood vessels in ischemic tissues. Macrophages have also been shown to infiltrate the corneal stroma and transdifferentiate into lymphatic endothelial cells.108 By overexpression of vascular endothelial growth factor, macrophages can be stimulated to transdifferentiate to the endothelial cell type.106 Pleiotrophin (PTN) expressed by macrophages under ischemic conditions can promote transdifferentiation of macrophages to endothelial cells both in vitro and in vivo. PTN-induced transdifferentiation of macrophages has been shown to be regulated at the transcription level by GATA-2 and GATA-3.109 Transdifferentiation of macrophage to other cell lineages, thus, cannot be ruled out, and reports in this direction will help us to understand macrophage plasticity more vividly.
Reprogramming
Although studies related to functional plasticity of macrophages are still in early stages, work has been performed to alter macrophage fate in vivo at desired sites. Discussed in the previous section, PTN can induce transdifferentiation of macrophage to endothelial cells. The authors demonstrated that under in vivo conditions in mice, the monocytic cells that express PTN get integrated into blood vessels.109 Tumor-infiltrating macrophages and TAMs have been described as suppressor macrophages that display anti-inflammatory and immunosuppressive activities.110,111 In vivo delivery of IL-12 to tumor sites results in the conversion of tumor-infiltrating macrophages and TAMs from the anti-inflammatory phenotype to the proinflammatory phenotype.112 IL-12–treated macrophages secrete IL-15, demonstrating their anti-inflammatory nature. IL-12 treatment could alter the function of these tumor-associated suppressor macrophages, reducing tumor supportive macrophage activities. Analysis of tumor-infiltrating macrophages and distal TAMs revealed that IL-12, both in vivo and in vitro, induced a rapid reduction of tumor-supportive macrophage activities (IL-10, monocyte chemoattractant protein-1, migration inhibitory factor, and TGF-β production) and a concomitant increase in proinflammatory and proimmunogenic activities.112
Macrophages are traditionally known to be derived from myeloid cells. However, it has been recently shown that induced pluripotent cells (iPSCs) can also produce functional macrophages,113 as shown by the generation of human iPS cell clones by lentivirus-mediated transfer of Yamanaka factor (Oct3/4, Sox2, c-Myc, and Klf4) transgenes into dermal fibroblasts, followed by treatment with granulocyte-macrophage CSF, macrophage CSF, and IL-4. Although iPSCs can produce macrophages, the functionality of the macrophage will be dependent on the source of iPSC. The evidence was provided by Jiang et al,114 who studied patients experiencing chronic granulomatous disease, an inherited disorder of macrophages in which NADPH oxidase is defective in generating ROS. In CGD patients, macrophages derived from iPSCs retain their phagocytic function but suffer from compromised ROS production.114 This evidence also supported the notion that macrophages originating from iPSCs behave similar to those originating from myeloid cells.
Perspectives
Monocytes and macrophages are versatile and plastic cells, and the function and phenotype of these cells are regulated by the signals from the local milieu. Macrophages may assume multiple phenotypes, depending on conditions at the region of interest. Therefore, the polarization of macrophages should be considered as a spectrum, of which the classical and alternative activation states represent two extremes in the state of macrophage polarization. The local environment of a tissue repair site is highly dynamic and responsive to the progressive healing or futile nonhealing outcomes. Thus, at the site of tissue injury, macrophages may exist at any one point in the continuum of macrophage polarization states. In addition, monocytes may transdifferentiate to several cell types influencing the fate of tissue repair. Current evidence in this direction is scanty but lays the foundation to warrant further investigation. Given the versatility of monocytes and macrophages at the site of tissue injury, together with their profound influence on repair outcomes, it will be of substantial therapeutic value to gain traction on interventions aimed at tuning macrophage fate at the site of tissue injury.
Regenerative Medicine Theme Issue
Footnotes
Supported by National Institute of Diabetes and Digestive and Kidney Diseases grant R01 DK076566 (S.R.), National Institute of Nursing Research grants NR015676 (S.R.) and NR013898 and NR015676 (C.K.S.), and National Institute of General Medical Sciences grants RO1 GM108014, GM069589, and GM 077185 (C.K.S.).
A.D. and M.S. contributed equally to this work.
Disclosures: None declared.
This article is part of a review series on regenerative medicine.
References
- 1.Sica A., Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122:787–795. doi: 10.1172/JCI59643. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Strauss O., Rod Dunbar P., Bartlett A., Phillips A. The immunophenotype of the antigen presenting cells of the mononuclear phagocyte system in the normal human liver: a systematic review. J Hepatol. 2015;62:458–468. doi: 10.1016/j.jhep.2014.10.006. [DOI] [PubMed] [Google Scholar]
- 3.Hume D.A., Ross I.L., Himes S.R., Sasmono R.T., Wells C.A., Ravasi T. The mononuclear phagocyte system revisited. J Leukoc Biol. 2002;72:621–627. [PubMed] [Google Scholar]
- 4.Taylor P.R., Gordon S. Monocyte heterogeneity and innate immunity. Immunity. 2003;19:2–4. doi: 10.1016/s1074-7613(03)00178-x. [DOI] [PubMed] [Google Scholar]
- 5.Hume D.A. Differentiation and heterogeneity in the mononuclear phagocyte system. Mucosal Immunol. 2008;1:432–441. doi: 10.1038/mi.2008.36. [DOI] [PubMed] [Google Scholar]
- 6.Hume D.A., MacDonald K.P. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood. 2012;119:1810–1820. doi: 10.1182/blood-2011-09-379214. [DOI] [PubMed] [Google Scholar]
- 7.Massberg S., Schaerli P., Knezevic-Maramica I., Kollnberger M., Tubo N., Moseman E.A., Huff I.V., Junt T., Wagers A.J., Mazo I.B., von Andrian U.H. Immunosurveillance by hematopoietic progenitor cells trafficking through blood, lymph, and peripheral tissues. Cell. 2007;131:994–1008. doi: 10.1016/j.cell.2007.09.047. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Serbina N.V., Jia T., Hohl T.M., Pamer E.G. Monocyte-mediated defense against microbial pathogens. Annu Rev Immunol. 2008;26:421–452. doi: 10.1146/annurev.immunol.26.021607.090326. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5:953–964. doi: 10.1038/nri1733. [DOI] [PubMed] [Google Scholar]
- 10.Sunderkotter C., Nikolic T., Dillon M.J., Van Rooijen N., Stehling M., Drevets D.A., Leenen P.J. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol. 2004;172:4410–4417. doi: 10.4049/jimmunol.172.7.4410. [DOI] [PubMed] [Google Scholar]
- 11.Geissmann F., Jung S., Littman D.R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 2003;19:71–82. doi: 10.1016/s1074-7613(03)00174-2. [DOI] [PubMed] [Google Scholar]
- 12.Italiani P., Boraschi D. From monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation. Front Immunol. 2014;5:514. doi: 10.3389/fimmu.2014.00514. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Mitchell A.J., Roediger B., Weninger W. Monocyte homeostasis and the plasticity of inflammatory monocytes. Cell Immunol. 2014;291:22–31. doi: 10.1016/j.cellimm.2014.05.010. [DOI] [PubMed] [Google Scholar]
- 14.Schauer D., Starlinger P., Zajc P., Alidzanovic L., Maier T., Buchberger E., Pop L., Gruenberger B., Gruenberger T., Brostjan C. Monocytes with angiogenic potential are selectively induced by liver resection and accumulate near the site of liver regeneration. BMC Immunol. 2014;15:50. doi: 10.1186/s12865-014-0050-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Fischman D.A., Hay E.D. Origin of osteoclasts from mononuclear leucocytes in regenerating newt limbs. Anat Rec. 1962;143:329–337. doi: 10.1002/ar.1091430402. [DOI] [PubMed] [Google Scholar]
- 16.Satpathy A.T., Wu X., Albring J.C., Murphy K.M. Re(de)fining the dendritic cell lineage. Nat Immunol. 2012;13:1145–1154. doi: 10.1038/ni.2467. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Gregorio J., Meller S., Conrad C., Di Nardo A., Homey B., Lauerma A., Arai N., Gallo R.L., Digiovanni J., Gilliet M. Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons. J Exp Med. 2010;207:2921–2930. doi: 10.1084/jem.20101102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Cella M., Jarrossay D., Facchetti F., Alebardi O., Nakajima H., Lanzavecchia A., Colonna M. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med. 1999;5:919–923. doi: 10.1038/11360. [DOI] [PubMed] [Google Scholar]
- 19.Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958–969. doi: 10.1038/nri2448. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Zalkind S. University Press of the Pacific; Honolulu, HI: 2001. Ilya Mechnikov: His Life and Work; p. 212. [Google Scholar]
- 21.Geissmann F., Manz M.G., Jung S., Sieweke M.H., Merad M., Ley K. Development of monocytes, macrophages, and dendritic cells. Science. 2010;327:656–661. doi: 10.1126/science.1178331. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Gordon S., Martinez F.O. Alternative activation of macrophages: mechanism and functions. Immunity. 2010;32:593–604. doi: 10.1016/j.immuni.2010.05.007. [DOI] [PubMed] [Google Scholar]
- 23.Das A., Ganesh K., Khanna S., Sen C.K., Roy S. Engulfment of apoptotic cells by macrophages: a role of microRNA-21 in the resolution of wound inflammation. J Immunol. 2014;192:1120–1129. doi: 10.4049/jimmunol.1300613. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Gardai S.J., Bratton D.L., Ogden C.A., Henson P.M. Recognition ligands on apoptotic cells: a perspective. J Leukoc Biol. 2006;79:896–903. doi: 10.1189/jlb.1005550. [DOI] [PubMed] [Google Scholar]
- 25.Tibrewal N., Wu Y., D'Mello V., Akakura R., George T.C., Varnum B., Birge R.B. Autophosphorylation docking site Tyr-867 in Mer receptor tyrosine kinase allows for dissociation of multiple signaling pathways for phagocytosis of apoptotic cells and down-modulation of lipopolysaccharide-inducible NF-kappaB transcriptional activation. J Biol Chem. 2008;283:3618–3627. doi: 10.1074/jbc.M706906200. [DOI] [PubMed] [Google Scholar]
- 26.van Furth R., Cohn Z.A. The origin and kinetics of mononuclear phagocytes. J Exp Med. 1968;128:415–435. doi: 10.1084/jem.128.3.415. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Jakubzick C., Gautier E.L., Gibbings S.L., Sojka D.K., Schlitzer A., Johnson T.E., Ivanov S., Duan Q., Bala S., Condon T., van Rooijen N., Grainger J.R., Belkaid Y., Ma'ayan A., Riches D.W., Yokoyama W.M., Ginhoux F., Henson P.M., Randolph G.J. Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. Immunity. 2013;39:599–610. doi: 10.1016/j.immuni.2013.08.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Yona S., Kim K.W., Wolf Y., Mildner A., Varol D., Breker M., Strauss-Ayali D., Viukov S., Guilliams M., Misharin A., Hume D.A., Perlman H., Malissen B., Zelzer E., Jung S. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity. 2013;38:79–91. doi: 10.1016/j.immuni.2012.12.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Ovchinnikov D.A. Macrophages in the embryo and beyond: much more than just giant phagocytes. Genesis. 2008;46:447–462. doi: 10.1002/dvg.20417. [DOI] [PubMed] [Google Scholar]
- 30.Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3:23–35. doi: 10.1038/nri978. [DOI] [PubMed] [Google Scholar]
- 31.Gigli I., Nelson R.A., Jr. Complement dependent immune phagocytosis, I: requirements for C'1, C'4, C'2, C'3. Exp Cell Res. 1968;51:45–67. doi: 10.1016/0014-4827(68)90158-4. [DOI] [PubMed] [Google Scholar]
- 32.Henson P.M., Bratton D.L., Fadok V.A. Apoptotic cell removal. Curr Biol. 2001;11:R795–R805. doi: 10.1016/s0960-9822(01)00474-2. [DOI] [PubMed] [Google Scholar]
- 33.Roy S., Sen C.K. In: Inflammation: A hallmark of obesity in conflict with wound healing. Obesity: Epidemiology, Pathophysiology, and Prevention, 2nd Edition. Bagchi D., Pruess H.G., editors. CRC Press; Boca Raton, FL: 2013. [Google Scholar]
- 34.Leibovich S.J., Ross R. The role of the macrophage in wound repair: a study with hydrocortisone and antimacrophage serum. Am J Pathol. 1975;78:71–100. [PMC free article] [PubMed] [Google Scholar]
- 35.Ferrante C.J., Leibovich S.J. Regulation of macrophage polarization and wound healing. Adv Wound Care (New Rochelle) 2012;1:10–16. doi: 10.1089/wound.2011.0307. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Sunderkotter C., Steinbrink K., Goebeler M., Bhardwaj R., Sorg C. Macrophages and angiogenesis. J Leukoc Biol. 1994;55:410–422. doi: 10.1002/jlb.55.3.410. [DOI] [PubMed] [Google Scholar]
- 37.El Khoury J., Hickman S.E., Thomas C.A., Cao L., Silverstein S.C., Loike J.D. Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature. 1996;382:716–719. doi: 10.1038/382716a0. [DOI] [PubMed] [Google Scholar]
- 38.Hanisch U.K., Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007;10:1387–1394. doi: 10.1038/nn1997. [DOI] [PubMed] [Google Scholar]
- 39.Ferrari D., Chiozzi P., Falzoni S., Dal Susino M., Collo G., Buell G., Di Virgilio F. ATP-mediated cytotoxicity in microglial cells. Neuropharmacology. 1997;36:1295–1301. doi: 10.1016/s0028-3908(97)00137-8. [DOI] [PubMed] [Google Scholar]
- 40.Aloisi F. Immune function of microglia. Glia. 2001;36:165–179. doi: 10.1002/glia.1106. [DOI] [PubMed] [Google Scholar]
- 41.Blinzinger K., Kreutzberg G. Displacement of synaptic terminals from regenerating motoneurons by microglial cells. Z Zellforsch Mikrosk Anat. 1968;85:145–157. doi: 10.1007/BF00325030. [DOI] [PubMed] [Google Scholar]
- 42.Minghetti L., Levi G. Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide. Prog Neurobiol. 1998;54:99–125. doi: 10.1016/s0301-0082(97)00052-x. [DOI] [PubMed] [Google Scholar]
- 43.Marchand F., Perretti M., McMahon S.B. Role of the immune system in chronic pain. Nat Rev Neurosci. 2005;6:521–532. doi: 10.1038/nrn1700. [DOI] [PubMed] [Google Scholar]
- 44.Schagat T.L., Wofford J.A., Wright J.R. Surfactant protein A enhances alveolar macrophage phagocytosis of apoptotic neutrophils. J Immunol. 2001;166:2727–2733. doi: 10.4049/jimmunol.166.4.2727. [DOI] [PubMed] [Google Scholar]
- 45.Sibille Y., Reynolds H.Y. Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis. 1990;141:471–501. doi: 10.1164/ajrccm/141.2.471. [DOI] [PubMed] [Google Scholar]
- 46.Weaver T.E., Whitsett J.A. Function and regulation of expression of pulmonary surfactant-associated proteins. Biochem J. 1991;273(Pt 2):249–264. doi: 10.1042/bj2730249. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Cline M.J. Histiocytes and histiocytosis. Blood. 1994;84:2840–2853. [PubMed] [Google Scholar]
- 48.Bouwens L., Baekeland M., De Zanger R., Wisse E. Quantitation, tissue distribution and proliferation kinetics of Kupffer cells in normal rat liver. Hepatology. 1986;6:718–722. doi: 10.1002/hep.1840060430. [DOI] [PubMed] [Google Scholar]
- 49.Klein A., Zhadkewich M., Margolick J., Winkelstein J., Bulkley G. Quantitative discrimination of hepatic reticuloendothelial clearance and phagocytic killing. J Leukoc Biol. 1994;55:248–252. doi: 10.1002/jlb.55.2.248. [DOI] [PubMed] [Google Scholar]
- 50.Udagawa N., Takahashi N., Akatsu T., Tanaka H., Sasaki T., Nishihara T., Koga T., Martin T.J., Suda T. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci U S A. 1990;87:7260–7264. doi: 10.1073/pnas.87.18.7260. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Odegaard J.I., Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science. 2013;339:172–177. doi: 10.1126/science.1230721. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Rosen E.D., Spiegelman B.M. Adipocytes as regulators of energy balance and glucose homeostasis. Nature. 2006;444:847–853. doi: 10.1038/nature05483. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Wynn T.A., Chawla A., Pollard J.W. Macrophage biology in development, homeostasis and disease. Nature. 2013;496:445–455. doi: 10.1038/nature12034. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Decker T., Kiderlen A.F., Lohmann-Matthes M.L. Liver macrophages (Kupffer cells) as cytotoxic effector cells in extracellular and intracellular cytotoxicity. Infect Immun. 1985;50:358–364. doi: 10.1128/iai.50.2.358-364.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Hiraiwa K., van Eeden S.F. Contribution of lung macrophages to the inflammatory responses induced by exposure to air pollutants. Mediators Inflamm. 2013;2013:619523. doi: 10.1155/2013/619523. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Timmons B.C., Fairhurst A.M., Mahendroo M.S. Temporal changes in myeloid cells in the cervix during pregnancy and parturition. J Immunol. 2009;182:2700–2707. doi: 10.4049/jimmunol.0803138. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549–555. doi: 10.1016/s1471-4906(02)02302-5. [DOI] [PubMed] [Google Scholar]
- 58.Biswas S.K., Gangi L., Paul S., Schioppa T., Saccani A., Sironi M., Bottazzi B., Doni A., Vincenzo B., Pasqualini F., Vago L., Nebuloni M., Mantovani A., Sica A. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation) Blood. 2006;107:2112–2122. doi: 10.1182/blood-2005-01-0428. [DOI] [PubMed] [Google Scholar]
- 59.Karin M., Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749–759. doi: 10.1038/nri1703. [DOI] [PubMed] [Google Scholar]
- 60.Biswas S.K., Sica A., Lewis C.E. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol. 2008;180:2011–2017. doi: 10.4049/jimmunol.180.4.2011. [DOI] [PubMed] [Google Scholar]
- 61.Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11:889–896. doi: 10.1038/ni.1937. [DOI] [PubMed] [Google Scholar]
- 62.Paletta-Silva R., Meyer-Fernandes J.R. Macrophage plasticity and polarization: cell signaling mechanisms and roles in immunity. Handbook of Macrophages. In: Takahashi R., Kai H., editors. NovaScience Publishers; Hauppauge, NY: 2012. pp. 147–174. [Google Scholar]
- 63.Biswas S.K., Chittezhath M., Shalova I.N., Lim J.Y. Macrophage polarization and plasticity in health and disease. Immunol Res. 2012;53:11–24. doi: 10.1007/s12026-012-8291-9. [DOI] [PubMed] [Google Scholar]
- 64.Stout R.D., Suttles J. T cell signaling of macrophage function in inflammatory disease. Front Biosci. 1997;2:197–206. doi: 10.2741/a183. [DOI] [PubMed] [Google Scholar]
- 65.Stout R.D., Suttles J. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol. 2004;76:509–513. doi: 10.1189/jlb.0504272. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Lech M., Grobmayr R., Weidenbusch M., Anders H.J. Tissues use resident dendritic cells and macrophages to maintain homeostasis and to regain homeostasis upon tissue injury: the immunoregulatory role of changing tissue environments. Mediators Inflamm. 2012;2012:951390. doi: 10.1155/2012/951390. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677–686. doi: 10.1016/j.it.2004.09.015. [DOI] [PubMed] [Google Scholar]
- 68.MacMicking J., Xie Q.W., Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol. 1997;15:323–350. doi: 10.1146/annurev.immunol.15.1.323. [DOI] [PubMed] [Google Scholar]
- 69.Galván-Peña S., O'Neill L.A.J. Metabolic reprograming in macrophage polarization. Front Immunol. 2014;5:1–6. doi: 10.3389/fimmu.2014.00420. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Martin P., Leibovich S.J. Inflammatory cells during wound repair: the good, the bad and the ugly. Trends Cell Biol. 2005;15:599–607. doi: 10.1016/j.tcb.2005.09.002. [DOI] [PubMed] [Google Scholar]
- 71.Brancato S.K., Albina J.E. Wound macrophages as key regulators of repair: origin, phenotype, and function. Am J Pathol. 2011;178:19–25. doi: 10.1016/j.ajpath.2010.08.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Daley J.M., Brancato S.K., Thomay A.A., Reichner J.S., Albina J.E. The phenotype of murine wound macrophages. J Leukoc Biol. 2010;87:59–67. doi: 10.1189/jlb.0409236. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Khanna S., Biswas S., Shang Y., Collard E., Azad A., Kauh C., Bhasker V., Gordillo G.M., Sen C.K., Roy S. Macrophage dysfunction impairs resolution of inflammation in the wounds of diabetic mice. PLoS One. 2010;5:e9539. doi: 10.1371/journal.pone.0009539. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Ganesh K., Das A., Dickerson R., Khanna S., Parinandi N.L., Gordillo G.M., Sen C.K., Roy S. Prostaglandin E(2) induces oncostatin M expression in human chronic wound macrophages through Axl receptor tyrosine kinase pathway. J Immunol. 2012;189:2563–2573. doi: 10.4049/jimmunol.1102762. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Murray P.J., Allen J.E., Biswas S.K., Fisher E.A., Gilroy D.W., Goerdt S., Gordon S., Hamilton J.A., Ivashkiv L.B., Lawrence T., Locati M., Mantovani A., Martinez F.O., Mege J.L., Mosser D.M., Natoli G., Saeij J.P., Schultze J.L., Shirey K.A., Sica A., Suttles J., Udalova I., van Ginderachter J.A., Vogel S.N., Wynn T.A. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41:14–20. doi: 10.1016/j.immuni.2014.06.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Porcheray F., Viaud S., Rimaniol A.C., Leone C., Samah B., Dereuddre-Bosquet N., Dormont D., Gras G. Macrophage activation switching: an asset for the resolution of inflammation. Clin Exp Immunol. 2005;142:481–489. doi: 10.1111/j.1365-2249.2005.02934.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Zheng X.F., Hong Y.X., Feng G.J., Zhang G.F., Rogers H., Lewis M.A., Williams D.W., Xia Z.F., Song B., Wei X.Q. Lipopolysaccharide-induced M2 to M1 macrophage transformation for IL-12p70 production is blocked by Candida albicans mediated up-regulation of EBI3 expression. PLoS One. 2013;8:e63967. doi: 10.1371/journal.pone.0063967. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Heusinkveld M., van der Burg S.H. Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med. 2011;9:216. doi: 10.1186/1479-5876-9-216. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Heusinkveld M., de Vos van Steenwijk P.J., Goedemans R., Ramwadhdoebe T.H., Gorter A., Welters M.J., van Hall T., van der Burg S.H. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol. 2011;187:1157–1165. doi: 10.4049/jimmunol.1100889. [DOI] [PubMed] [Google Scholar]
- 80.Rodriguez-Prados J.C., Traves P.G., Cuenca J., Rico D., Aragones J., Martin-Sanz P., Cascante M., Bosca L. Substrate fate in activated macrophages: a comparison between innate, classic, and alternative activation. J Immunol. 2010;185:605–614. doi: 10.4049/jimmunol.0901698. [DOI] [PubMed] [Google Scholar]
- 81.Rehman J., Li J., Orschell C.M., March K.L. Peripheral blood “endothelial progenitor cells” are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation. 2003;107:1164–1169. doi: 10.1161/01.cir.0000058702.69484.a0. [DOI] [PubMed] [Google Scholar]
- 82.Rohde E., Malischnik C., Thaler D., Maierhofer T., Linkesch W., Lanzer G., Guelly C., Strunk D. Blood monocytes mimic endothelial progenitor cells. Stem Cells. 2006;24:357–367. doi: 10.1634/stemcells.2005-0072. [DOI] [PubMed] [Google Scholar]
- 83.Lawrence T., Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol. 2011;11:750–761. doi: 10.1038/nri3088. [DOI] [PubMed] [Google Scholar]
- 84.Grinberg S., Hasko G., Wu D., Leibovich S.J. Suppression of PLCbeta2 by endotoxin plays a role in the adenosine A(2A) receptor-mediated switch of macrophages from an inflammatory to an angiogenic phenotype. Am J Pathol. 2009;175:2439–2453. doi: 10.2353/ajpath.2009.090290. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85.Rauh M.J., Ho V., Pereira C., Sham A., Sly L.M., Lam V., Huxham L., Minchinton A.I., Mui A., Krystal G. SHIP represses the generation of alternatively activated macrophages. Immunity. 2005;23:361–374. doi: 10.1016/j.immuni.2005.09.003. [DOI] [PubMed] [Google Scholar]
- 86.Ruffell D., Mourkioti F., Gambardella A., Kirstetter P., Lopez R.G., Rosenthal N., Nerlov C. A CREB-C/EBPbeta cascade induces M2 macrophage-specific gene expression and promotes muscle injury repair. Proc Natl Acad Sci U S A. 2009;106:17475–17480. doi: 10.1073/pnas.0908641106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87.Sag D., Carling D., Stout R.D., Suttles J. Adenosine 5 '-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J Immunol. 2008;181:8633–8641. doi: 10.4049/jimmunol.181.12.8633. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88.Mounier R., Theret M., Arnold L., Cuvellier S., Bultot L., Goransson O., Sanz N., Ferry A., Sakamoto K., Foretz M., Viollet B., Chazaud B. AMPK alpha 1 regulates macrophage skewing at the time of resolution of inflammation during skeletal muscle regeneration. Cell Metab. 2013;18:251–264. doi: 10.1016/j.cmet.2013.06.017. [DOI] [PubMed] [Google Scholar]
- 89.Perdiguero E., Sousa-Victor P., Ruiz-Bonilla V., Jardi M., Caelles C., Serrano A.L., Munoz-Canoves P. p38/MKP-1-regulated AKT coordinates macrophage transitions and resolution of inflammation during tissue repair. J Cell Biol. 2011;195:307–322. doi: 10.1083/jcb.201104053. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 90.Arranz A., Doxaki C., Vergadi E., Martinez de la Torre Y., Vaporidi K., Lagoudaki E.D., Ieronymaki E., Androulidaki A., Venihaki M., Margioris A.N., Stathopoulos E.N., Tsichlis P.N., Tsatsanis C. Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization. Proc Natl Acad Sci U S A. 2012;109:9517–9522. doi: 10.1073/pnas.1119038109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91.Correll P.H., Iwama A., Tondat S., Mayrhofer G., Suda T., Bernstein A. Deregulated inflammatory response in mice lacking the STK/RON receptor tyrosine kinase. Genes Funct. 1997;1:69–83. doi: 10.1046/j.1365-4624.1997.00009.x. [DOI] [PubMed] [Google Scholar]
- 92.Chaudhuri A. Regulation of macrophage polarization by RON receptor tyrosine kinase signaling. Front Immunol. 2014;5:546. doi: 10.3389/fimmu.2014.00546. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 93.Sen C.K. Wound healing essentials: let there be oxygen. Wound Repair Regen. 2009;17:1–18. doi: 10.1111/j.1524-475X.2008.00436.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 94.Krek A., Grun D., Poy M.N., Wolf R., Rosenberg L., Epstein E.J., MacMenamin P., da Piedade I., Gunsalus K.C., Stoffel M., Rajewsky N. Combinatorial microRNA target predictions. Nat Genet. 2005;37:495–500. doi: 10.1038/ng1536. [DOI] [PubMed] [Google Scholar]
- 95.Banerjee S., Xie N., Cui H.C., Tan Z., Yang S.Z., Icyuz M., Abraham E., Liu G. MicroRNA let-7c regulates macrophage polarization. J Immunol. 2013;190:6542–6549. doi: 10.4049/jimmunol.1202496. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 96.Maitra U., Gan L., Chang S., Li L.W. Low-dose endotoxin induces inflammation by selectively removing nuclear receptors and activating CCAAT/enhancer-binding protein delta. J Immunol. 2011;186:4467–4473. doi: 10.4049/jimmunol.1003300. [DOI] [PubMed] [Google Scholar]
- 97.Ponomarev E.D., Veremeyko T., Barteneva N., Krichevsky A.M., Weiner H.L. MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-alpha-PU.1 pathway. Nat Med. 2011;17:64–70. doi: 10.1038/nm.2266. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 98.Zhuang G.Q., Meng C., Guo X., Cheruku P.S., Shi L., Xu H., Li H.G., Wang G., Evans A.R., Safe S., Wu C.D., Zhou B.Y. A novel regulator of macrophage activation miR-223 in obesity-associated adipose tissue inflammation. Circulation. 2012;125:2892–2903. doi: 10.1161/CIRCULATIONAHA.111.087817. [DOI] [PubMed] [Google Scholar]
- 99.Reddy M.A., Chen Z., Park J.T., Wang M., Lanting L., Zhang Q., Bhatt K., Leung A., Wu X., Putta S., Saetrom P., Devaraj S., Natarajan R. Regulation of inflammatory phenotype in macrophages by a diabetes-induced long non-coding RNA. Diabetes. 2014;63:4249–4261. doi: 10.2337/db14-0298. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 100.Li Z., Chao T.C., Chang K.Y., Lin N., Patil V.S., Shimizu C., Head S.R., Burns J.C., Rana T.M. The long noncoding RNA THRIL regulates TNFalpha expression through its interaction with hnRNPL. Proc Natl Acad Sci U S A. 2014;111:1002–1007. doi: 10.1073/pnas.1313768111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 101.Hirose K., Iwabuchi K., Shimada K., Kiyanagi T., Iwahara C., Nakayama H., Daida H. Different responses to oxidized low-density lipoproteins in human polarized macrophages. Lipids Health Dis. 2011;10:1. doi: 10.1186/1476-511X-10-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 102.Samuelsson B., Dahlen S.E., Lindgren J.A., Rouzer C.A., Serhan C.N. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. 1987;237:1171–1176. doi: 10.1126/science.2820055. [DOI] [PubMed] [Google Scholar]
- 103.Serhan C.N. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol. 2007;25:101–137. doi: 10.1146/annurev.immunol.25.022106.141647. [DOI] [PubMed] [Google Scholar]
- 104.Hong S., Porter T.F., Lu Y., Oh S.F., Pillai P.S., Serhan C.N. Resolvin E1 metabolome in local inactivation during inflammation-resolution. J Immunol. 2008;180:3512–3519. doi: 10.4049/jimmunol.180.5.3512. [DOI] [PubMed] [Google Scholar]
- 105.Dalli J., Serhan C.N. Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood. 2012;120:E60–E72. doi: 10.1182/blood-2012-04-423525. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 106.Yan D., Wang X., Li D., Qu Z., Ruan Q. Macrophages overexpressing VEGF, transdifferentiate into endothelial-like cells in vitro and in vivo. Biotechnol Lett. 2011;33:1751–1758. doi: 10.1007/s10529-011-0645-1. [DOI] [PubMed] [Google Scholar]
- 107.Kim S.J., Kim J.S., Papadopoulos J., Wook Kim S., Maya M., Zhang F., He J., Fan D., Langley R., Fidler I.J. Circulating monocytes expressing CD31: implications for acute and chronic angiogenesis. Am J Pathol. 2009;174:1972–1980. doi: 10.2353/ajpath.2009.080819. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 108.Maruyama K., Ii M., Cursiefen C., Jackson D.G., Keino H., Tomita M., Van Rooijen N., Takenaka H., D'Amore P.A., Stein-Streilein J., Losordo D.W., Streilein J.W. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest. 2005;115:2363–2372. doi: 10.1172/JCI23874. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 109.Sharifi B.G., Zeng Z., Wang L., Song L., Chen H., Qin M., Sierra-Honigmann M.R., Wachsmann-Hogiu S., Shah P.K. Pleiotrophin induces transdifferentiation of monocytes into functional endothelial cells. Arterioscler Thromb Vasc Biol. 2006;26:1273–1280. doi: 10.1161/01.ATV.0000222017.05085.8e. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 110.Bronte V., Serafini P., Apolloni E., Zanovello P. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J Immunother. 2001;24:431–446. doi: 10.1097/00002371-200111000-00001. [DOI] [PubMed] [Google Scholar]
- 111.Gabrilovich D.I., Velders M.P., Sotomayor E.M., Kast W.M. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol. 2001;166:5398–5406. doi: 10.4049/jimmunol.166.9.5398. [DOI] [PubMed] [Google Scholar]
- 112.Watkins S.K., Egilmez N.K., Suttles J., Stout R.D. IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J Immunol. 2007;178:1357–1362. doi: 10.4049/jimmunol.178.3.1357. [DOI] [PubMed] [Google Scholar]
- 113.Senju S., Haruta M., Matsumura K., Matsunaga Y., Fukushima S., Ikeda T., Takamatsu K., Irie A., Nishimura Y. Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapy. Gene Ther. 2011;18:874–883. doi: 10.1038/gt.2011.22. [DOI] [PubMed] [Google Scholar]
- 114.Jiang Y., Cowley S.A., Siler U., Melguizo D., Tilgner K., Browne C., Dewilton A., Przyborski S., Saretzki G., James W.S., Seger R.A., Reichenbach J., Lako M., Armstrong L. Derivation and functional analysis of patient-specific induced pluripotent stem cells as an in vitro model of chronic granulomatous disease. Stem Cells. 2012;30:599–611. doi: 10.1002/stem.1053. [DOI] [PMC free article] [PubMed] [Google Scholar]